PML

Protein PML · P29590 · PML on Sugi Atlas →

0 patent compounds predicted against PML, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PML by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis PHASE4COMPLETED
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting PHASE4RECRUITING
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) PHASE3COMPLETED
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis PHASE3COMPLETED
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) PHASE3COMPLETED
Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL). PHASE3RECRUITING
Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease. PHASE3COMPLETED
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis PHASE3ACTIVE_NOT_RECRUITING
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease PHASE3COMPLETED
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease PHASE3ACTIVE_NOT_RECRUITING
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS PHASE3COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML PHASE2UNKNOWN
Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma PHASE1/PHASE2WITHDRAWN
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma PHASE2RECRUITING
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) PHASE2RECRUITING
T-cell Therapy in Patients With PML PHASE2RECRUITING
Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD PHASE2NOT_YET_RECRUITING
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) PHASE1/PHASE2RECRUITING
Brentuximab Vedotin for Systemic Sclerosis PHASE1/PHASE2COMPLETED
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) PHASE2ACTIVE_NOT_RECRUITING
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid PHASE1UNKNOWN
A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants PHASE1COMPLETED
Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART PHASE1ENROLLING_BY_INVITATION
Observational Study on Characteristics and Survival Correlates of Progressive Multifocal Leukoencephalopathy (PML) in Italy nanCOMPLETED
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML) nanRECRUITING
Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML) nanCOMPLETED
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy nanCOMPLETED
Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod nanCOMPLETED
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PML binder may also engage these)

ProteinNameSimilarity
TERF2IP Telomeric repeat-binding factor 2-interacting protein 1 0.976 landscape →
P97260 0.976 P97260 →
A2RRU4 0.975 A2RRU4 →
Q8N1F8 0.975 Q8N1F8 →
Q8CE64 0.975 Q8CE64 →
Q3TAA7 0.974 Q3TAA7 →
Q5MNU5 0.974 Q5MNU5 →
Q69Z89 0.973 Q69Z89 →
P50555 0.973 P50555 →
E9PGG2 0.972 E9PGG2 →
Q96G42 0.972 Q96G42 →
Q496Y0 0.971 Q496Y0 →
Q8C190 0.970 Q8C190 →
Q70EL4 0.970 Q70EL4 →
Q4R4I0 0.969 Q4R4I0 →
Q9Y2B5 0.969 Q9Y2B5 →
Q7TNM2 0.969 Q7TNM2 →
Q9BT49 0.968 Q9BT49 →
Q9DD19 0.968 Q9DD19 →
Q5JSP0 0.968 Q5JSP0 →
Q8N554 0.968 Q8N554 →
E1BBQ2 0.967 E1BBQ2 →
Q7Z4K8 0.967 Q7Z4K8 →
Q8C0R7 0.967 Q8C0R7 →
P49797 0.966 P49797 →
Q6GQT6 0.966 Q6GQT6 →
Q8BUM9 0.966 Q8BUM9 →
Q8HXH0 0.966 Q8HXH0 →
Q96JH8 0.966 Q96JH8 →
TNFRSF1A Tumor necrosis factor receptor superfamily member 1A 0.966 landscape →